RxDoctor Payments Data

Robert Wielenga, MD

Family Medicine · Downey, CANPI 1952469850

Payments from drug & device makers

$9,610in general payments, 2019–2025

Across 607 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$1K
  • Lilly USA, LLC$951
  • GSK$737
  • AbbVie$700
  • Johnson & Johnson$606
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,609100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,610 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$125,445
Medicare patients
250
Services billed
1,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide371$479,859
JardianceEmpagliflozin252$323,821
ProliaDenosumab118$194,357
TrulicityDulaglutide143$178,862
JanuviaSitagliptin Phosphate150$172,296
XareltoRivaroxaban150$159,362
EliquisApixaban132$155,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter138$138,579
TymlosAbaloparatide32$87,348
VascepaIcosapent Ethyl66$60,443
MyrbetriqMirabegron62$54,032
LinzessLinaclotide42$47,092
JanumetSitagliptin Phos/Metformin Hcl37$46,505
Repatha SureclickEvolocumab51$45,066
TradjentaLinagliptin35$44,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,304$479,859371 claims
Boehringer IngelheimJardiance, Tradjenta$315$368,208287 claims
MerckJanuvia, Janumet, Janumet Xr$17$260,746233 claims
Lilly USA, LLCTrulicity, Mounjaro$951$219,683172 claims
AmgenProlia$1,236$194,357118 claims
GSKTrelegy Ellipta, Breo Ellipta$737$166,454191 claims
Johnson & JohnsonXarelto$606$159,362150 claims
PfizerEliquis$200$155,694132 claims
Radius Health, Inc.Tymlos$514$87,34832 claims
AbbVieLinzess, Creon$700$72,56558 claims
Astellas Pharma US IncMyrbetriq$24$54,03262 claims
AstraZenecaFarxiga$354$37,35233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →